Workflow
Lumentum(LITE) - 2026 Q1 - Earnings Call Presentation
2025-11-04 22:00
Q1 FY26 Results - The company's Q1 FY26 revenue reached $533.8 million[12, 13, 15], compared to $480.7 million in Q4 FY25[12, 13] and $336.9 million in Q1 FY25[12, 13], demonstrating a significant year-over-year increase of 64%[11] - GAAP gross margin was 34.0%[12], while non-GAAP gross margin was 39.4%[13] - GAAP operating income was $6.7 million[12], a significant improvement from an $82.4 million loss in Q1 FY25[12], while non-GAAP operating income was $99.8 million[13], compared to $10.0 million in Q1 FY25[13] - GAAP diluted EPS was $0.05[12], compared to $(1.21) in Q1 FY25[12], while non-GAAP diluted EPS was $1.10[13], compared to $0.18 in Q1 FY25[13] Revenue Breakdown & Key Drivers - Systems revenue increased 47% year-over-year, driven by cloud transceivers[11] - Cloud and AI business is accelerating, driving Q1 revenue up 58% and expanding operating margin >1,500 bps (YoY basis)[11] - 3D sensing revenue is below 5% of total company revenue[11] Q2 FY26 Guidance - The company projects Q2 FY26 revenue between $630 million and $670 million[15] - The company anticipates a non-GAAP operating margin between 20.0% and 22.0% for Q2 FY26[15] - The company expects non-GAAP diluted EPS to be between $1.30 and $1.50 for Q2 FY26[15]
Bowlero (BOWL) - 2026 Q1 - Earnings Call Presentation
2025-11-04 22:00
Business Overview - Lucky Strike operates 369 locations as of November 2025, well-positioned in attractive North American markets and expanding into Family Entertainment Centers (FECs) through the acquisition of Boomers[24] - The company's diversified portfolio includes bowling (46%), food & beverage (35%), and amusement & other (19%) revenue streams in FY25, mitigating seasonality and consumer discretionary spending risks[26] Financial Performance - Total Revenue increased by 4% from $1,154,614 thousand in FY24 to $1,201,333 thousand in FY25[55] - Same Store Revenue decreased by 3.7% from $1,029,251 thousand in FY24 to $990,678 thousand in FY25[55] - Adjusted EBITDA increased from $361,497 thousand in FY24 to $367,687 thousand in FY25, with margins of 31.3% and 30.6% respectively[59] - Adjusted Location EBITDA margin was 36% in Q1 FY25, 42% in Q2 FY25, 44% in Q3 FY25, and 40% in Q4 FY25[57] Strategic Initiatives - The company sold 260,000 summer passes in 2025, with members visiting 9 times per pass, driving loyalty and year-round revenue[18] - Lucky Strike plans to rebrand nearly 100 locations by the end of the year and complete the rebrand by the end of 2026[33] Acquisitions and Value Creation - Lucky Strike acquired AMF for $310 million in 2013, with Lucky Strike contributing $20 million of equity, resulting in an estimated value creation of $1.3-$1.5 billion[20] - The company acquired Brunswick locations in 2014 for $260 million and immediately entered into a Sale-Leaseback Transaction reducing purchase price to $60 million[20, 21] - The company deployed $700 million of capital into acquisitions in the past three years[21]
Clover Health Investments(CLOV) - 2025 Q3 - Earnings Call Presentation
2025-11-04 22:00
Financial Performance - 3Q25 Medicare Advantage membership increased by 35% year-over-year[8] - 3Q25 Insurance revenue increased by 49% year-over-year[8] - 3Q25 Adjusted EBITDA and Adjusted Net income were $2 million[8] - 3Q YTD Adjusted EBITDA was $45 million and Adjusted Net income was $44 million[8] - 3Q25 Adjusted SG&A as a % of Total revenues improved by 370 bps year-over-year[8] - Updated FY25 Guidance: Insurance Revenue is expected to be $1.85 billion - $1.88 billion[36], Adjusted SG&A is expected to be $325 million - $335 million[36], Adjusted EBITDA is expected to be $15 million - $30 million[36], and Average Medicare Advantage Membership is expected to be 106,000 - 108,000[36] Clinical Model and Technology - Clover Health's Medicare Advantage PPO plans received a score of 4.72 / 5 Stars on HEDIS Measures for Star Rating Year 2026[33] - Clover Assistant enables better care for patients from socioeconomically disadvantaged neighborhoods, with higher diagnosis rates of diabetes (75% higher), CKD (89% higher), CHF (89% higher) and COPD (70% higher)[29] Future Outlook - Clover Health expects to achieve FY26 GAAP Net income[8] - Clover Health is well-positioned for above-market growth & profitability expansion in 2026 & beyond[9]
Accel Entertainment(ACEL) - 2025 Q3 - Earnings Call Presentation
2025-11-04 22:00
Company Overview - Accel operates over 27,700 gaming machines in neighborhood restaurants, bars, and other local businesses[9] - The company has 4,451 local retail partners across 10 states[9] - Accel has contributed $134 billion in taxes since January 2021 to support state and local governments[9] Financial Performance - Q3 2025 revenues reached $330 million, a 91% increase compared to Q3 2024[22] - Excluding acquisitions, Q3 2025 revenue was $310 million, a 26% increase year-over-year[24] - Net income for Q3 2025 was $13 million, a 1718% increase compared to Q3 2024[24] - Adjusted EBITDA for Q3 2025 was $51 million, an 115% increase compared to Q3 2024[24] Capital Allocation - A new $900 million credit facility was closed, extending maturities to 2030[21] - As of Q3 2025, $167 million of Accel Class A-1 Common Stock has been repurchased since November 2021[27] Expansion and Growth - The number of locations increased by 4% from 4,289 in Q3 2024 to 4,451 in Q3 2025[34] - The number of terminals increased by 5% from 26,509 in Q3 2024 to 27,714 in Q3 2025[34]
SuRo Capital(SSSS) - 2025 Q3 - Earnings Call Presentation
2025-11-04 22:00
Financial Performance - SuRo Capital's Net Asset Value (NAV) per share as of September 30, 2025, is $9.23, with net assets of approximately $231.8 million at quarter-end[7], an increase from the dividend-adjusted $8.93 per share as of June 30, 2025[7] - A cash dividend of $0.25 per share was declared on November 3, 2025, payable on December 5 to shareholders of record as of November 21[7] - Net investment loss for the third quarter ended September 30, 2025, was $3.5 million, or $0.14 per share[29] - Net realized gain on investments for the third quarter was $5.2 million, or $0.21 per share[29] - Net change in unrealized appreciation of investments was $5.7 million, or $0.23 per share[29] Investment Activities - A $0.3 million follow-on convertible debt investment was made in Supplying Demand, Inc (d/b/a Liquid Death)[9, 23] - A $5.0 million preferred shares investment was made in HL Digital Assets Inc[9, 23] - Total distributions from CW Opportunity 2 LP to date were $14.2 million, resulting in $10.0 million realized gains[7] - Net proceeds from GrabAGun Digital Holdings, Inc warrants were $0.7 million, resulting in $0.5 million realized gains[7] Portfolio Composition - The top 5 positions account for approximately 52% of the investment portfolio at fair value as of September 30, 2025[25] - Artificial Intelligence Infrastructure & Applications represents 30.5% of the portfolio fair value, totaling $76.9 million[27]
Cryoport(CYRX) - 2025 Q3 - Earnings Call Presentation
2025-11-04 22:00
Financial Performance - Cryoport's Q3 2025 revenue reached $4423 million, a 15% year-over-year increase[8, 13] - Life Sciences Services revenue increased by 16% to $24258 million in Q3 2025[11, 13] - Life Sciences Products revenue increased by 15% to $19975 million in Q3 2025[11, 13] - BioServices & Biostorage revenue increased by 21% in Q3 2025[11] - Commercial Cell & Gene Therapy revenue grew by 36% year-over-year to $83 million in Q3 2025[8, 11, 17] - Cryoport revised its full-year 2025 revenue guidance to $170 - $174 million[8] - Cryoport has $421 million in cash and short-term investments[8, 15] - Gross margin from continuing operations was 482%[15, 26] - Adjusted EBITDA from continuing operations was $(06) million[15] Operational Highlights - Cryoport supports 19 commercial Cell & Gene Therapies[8, 21] - Cryoport supports 745 active Cell & Gene Therapy clinical trials[8, 20, 24] - Cryoport supports 83 Phase III clinical trials[18, 20] - Cryoport supports approximately 70% of all industry clinical trials[24]
Axon(AXON) - 2025 Q3 - Earnings Call Presentation
2025-11-04 22:00
Company Overview - Axon's mission is to protect life by building the technology ecosystem for public safety[7] - The company estimates a total addressable market of $159 billion[9, 68] - Axon has over 1 million software users and has sold over 1 million TASER devices[9] Financial Performance - Axon's 2024 annual revenue was $2.1 billion[32] - The company's annual recurring revenue was $1.3 billion[34] - Future contracted bookings reached $11.4 billion[34, 122] - The adjusted EBITDA margin for 2024 was 25%[34] - Net revenue retention was 124%[34, 82, 123] Market Opportunity - The U S State & Local Law Enforcement TAM is under 15% penetrated[63] - Law enforcement use cases account for approximately 50% of the total addressable market[62] - U S State & Local law enforcement accounted for approximately 75% of company revenue in 2024[66] Forward-Looking Statements - Axon projects Q4 2025 revenue between $750 million and $755 million, representing approximately 31% annual growth[127] - The company anticipates an adjusted EBITDA of $178 million to $182 million for Q4 2025, with an approximate 24% margin[127] - Axon expects approximately $2.74 billion in revenue for the full year 2025, a growth of approximately 31%[127]
Clearway Energy(CWEN) - 2025 Q3 - Earnings Call Presentation
2025-11-04 22:00
Financial Performance & Guidance - Clearway Energy narrowed its 2025 Cash Available for Distribution (CAFD) guidance to the top half of the original range, targeting $420-440 million[13] - The company established a 2030 CAFD per share target of $2.90-3.10, representing a 7-8% compound annual growth rate (CAGR) from 2025-2030[13] - Clearway Energy set the 2026 CAFD guidance range at $470-510 million[61] - The company is targeting 2026 Dividend Per Share (DPS) growth of 6.5%, consistent with prior commitments[65] - Third quarter 2025 Adjusted EBITDA reached $385 million, with year-to-date (YTD) figures at $980 million[58] - Third quarter 2025 CAFD was $166 million, bringing the YTD total to $395 million[58] Growth Strategy & Pipeline - Clearway Group's late-stage project pipeline includes approximately 11 GW of projects through 2032[96] - The company has signed or been awarded 1.8 GW of Power Purchase Agreements (PPAs) to supply data centers[13] - Clearway Energy is targeting CAFD yields of approximately 10.5% on future investments for 2028 COD vintages and beyond[13] Capital Allocation & Funding - Clearway Energy plans to deploy >=$2.5 billion between 2026-2029 to meet its 2030 goals[69] - The company anticipates that retained cash flows will become a growing source of funding, targeting a payout ratio approaching 70% by 2030[13] - Clearway Energy is targeting a payout ratio of less than 70% after 2030 to increase de-risked funding sources for growth of 5-8+% in 2031+[13]
AMD(AMD) - 2025 Q3 - Earnings Call Presentation
2025-11-04 22:00
Financial Performance - AMD reported record Q3 2025 revenue of $9.2 billion, a 36% year-over-year increase[17] - The GAAP gross margin was 52%, up 2 percentage points year-over-year[21,29] - Non-GAAP gross margin was 54%, flat year-over-year[21,30] - GAAP diluted earnings per share (EPS) increased 60% year-over-year to $0.75[27,29] - Non-GAAP diluted EPS increased 30% year-over-year to $1.20[27,30] Segment Results - Data Center revenue reached $4.3 billion, a 22% year-over-year increase[31,34] - Client & Gaming segment revenue was $4.0 billion, up 73% year-over-year[31,36] - Embedded segment revenue was $857 million, down 8% year-over-year[31,37] Q4 2025 Outlook (Non-GAAP) - Revenue is expected to be approximately $9.6 billion, plus or minus $300 million[38] - Gross margin is projected to be around 54.5%[38]
Exelixis(EXEL) - 2025 Q3 - Earnings Call Presentation
2025-11-04 22:00
TUESDAY, NOVEMBER 4, 2025 Third Quarter 2025 Financial Results Nasdaq: EXEL Today's Agenda | Introduction | Susan Hubbard | | --- | --- | | | EVP, Public Affairs and Investor Relations | | Third Quarter 2025 Highlights | Michael M. Morrissey, Ph.D. | | | President and CEO | | Financial Results & Guidance | Chris Senner | | | EVP and CFO | | Research & Development Update | Dana T. Aftab, Ph.D. | | | EVP, Research and Development | | Commercial Update | PJ Haley | | | EVP, Commercial | Q&A All Participants 2 ...